International anti-cancer experts released updated draft guidelines for prostate cancer testing at the World Cancer Congress on April 4, hoping to reduce overdiagnosis and overmedication of prostate cancer. The prostate-specific antigen (PSA) test is one of the main tests for prostate cancer and is based on the concentration of PSA in the blood. However, there are other causes of elevated PSA levels besides prostate cancer, so the test can often result in a “false positive” diagnosis and subject patients to unnecessary and harmful treatment. As early as 2012, the U.S. Preventive Services Task Force, which guides physicians, issued a warning that current PSA testing guidelines could lead to overdiagnosis and overmedication. In response to the risk of misdiagnosis, a number of international cancer agencies and health experts collaborated to write the new testing guidelines, which provide advice on who should be tested and when. Australian Cancer Council expert Professor Orff told reporters that the new principles believe that PSA testing should only be performed between the ages of 45 and 69 if a person has no relevant symptoms; if a person’s expected survival time does not exceed seven years, PSA testing should not be performed because the test will not help extend life expectancy in this case; in addition, people without symptoms who undergo PSA testing do not need to undergo rectal The latter does not provide additional benefit. The new draft guidelines were discussed at the Congress and will be submitted to the Australian National Health and Medical Research Council for further discussion. After endorsement, it will be sent to all prostate cancer providers and urologists to provide guidance for their work. The 2014 World Cancer Congress was held December 3-6 in Melbourne, Australia’s second largest city, under the theme “Prevention, Detection and Treatment. At a symposium held on the 3rd, experts generally agreed that advances in cancer-fighting technology have made cancer less of a death sentence.